Last reviewed · How we verify
Sipuleucel-T with Booster
At a glance
| Generic name | Sipuleucel-T with Booster |
|---|---|
| Sponsor | Dendreon |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T (PHASE2)
- Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer (PHASE2)
- PROvenge Treatment and Early Cancer Treatment (PHASE3)
- Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (PHASE2)
- Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |